TERN - Company ID 0001831363
The table below shows Terns Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | $0.00 | $1.00M | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $32.23M |
Terns Pharmaceuticals, Inc. reported annual revenue of $0.00 for fiscal year 2022. That is down 100.0% from $1.00M in fiscal 2021. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $31.76M |
| $39.06M |
| $22.41M |
| $19.55M |
| $9.00M |
| Operating income | -$110.12M | -$101.87M | -$102.56M | -$62.03M | -$49.86M | -$37.02M |
| Income tax | $581.00K | $260.00K | $239.00K | $358.00K | $508.00K | $813.00K |
| Net income | -$96.21M | -$88.85M | -$90.21M | -$60.34M | -$50.16M | -$40.05M |
| EPS (diluted) | -$1.03 | -$1.12 | -$1.27 | -$1.67 | -$2.21 | - |